Invention Grant
US07666874B2 Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
有权
用于嗜酸性粒细胞综合征的嘧啶基氨基苯甲酰胺衍生物
- Patent Title: Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome
- Patent Title (中): 用于嗜酸性粒细胞综合征的嘧啶基氨基苯甲酰胺衍生物
-
Application No.: US11911562Application Date: 2006-05-02
-
Publication No.: US07666874B2Publication Date: 2010-02-23
- Inventor: Paul W. Manley , Jürgen Mestan , Doriano Fabbro
- Applicant: Paul W. Manley , Jürgen Mestan , Doriano Fabbro
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Matthew Mulkeen
- International Application: PCT/EP2006/004084 WO 20060502
- International Announcement: WO2006/117185 WO 20061109
- Main IPC: A61K31/506
- IPC: A61K31/506 ; C07D401/14 ; A61P7/00 ; A61P35/02
Abstract:
The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of FIP1L1-PDGFRα-induced or TEL-PDGFRβ-induced myeloproliferative diseases, especially for the curative and/or prophylactic treatment of hypereosinophilic syndrome and hypereosinophilic syndrome with resistance to imatinib, and to a method of treating hypereosinophilic syndrome, chronic eosinophilic leukemia and hypereosinophilic syndrome with resistance to imatinib, or other diseases associated with FIP1L1-PDGFRα, TEL-PDGFRβ or similar mutations that activate PDGFR.
Public/Granted literature
- US20080227800A1 Pyrimidylaminobenzamide Derivatives for Hypereosinophilic Syndrome Public/Granted day:2008-09-18
Information query
IPC分类:
